A multicenter, retrospective analysis of elderly patients with acute myeloid leukemia who were treated with decitabine

Decitabine is widely accepted as the treatment options for elderly acute myeloid leukemia (AML) patients. However, the efficacy has yet been assessed in Asian population. We retrospectively analyzed the outcomes of 80 Korean elderly AML patients who were treated with decitabine. The median age was 7...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Jun Ho, Park, Silvia, Kim, Jung Han, Won, Young-Woong, Lim, Do Hyoung, Han, Boram, Uhm, Jieun, Kim, Hae Su, Jung, Chul Won, Jang, Jun Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814236/
https://www.ncbi.nlm.nih.gov/pubmed/29464096
http://dx.doi.org/10.18632/oncotarget.23823
Descripción
Sumario:Decitabine is widely accepted as the treatment options for elderly acute myeloid leukemia (AML) patients. However, the efficacy has yet been assessed in Asian population. We retrospectively analyzed the outcomes of 80 Korean elderly AML patients who were treated with decitabine. The median age was 74 years (range, 64 to 86 years) and 6 (7.5%), 48 (60.0%), and 25 (31.3%) patients were categorized to favorable, intermediate, and poor risk group, respectively. The median OS was 10.2 months (95% CI 5.0–15.4). Given that decitabine treatment demonstrated improved clinical outcomes, it could be considered as one of the first-line treatment for Korean elderly AML patients.

Ejemplares similares